Recent Advance in Drug Development of Squamous Cell Carcinoma

Author(s): Jun Lei, Bing Fu, Hang Yin, Guanxiu Tang, Shujuan Zhu, Chunli Yan, Quanyong He

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 15 , Issue 7 , 2015

Become EABM
Become Reviewer

Graphical Abstract:


Squamous cell carcinoma (SCC) has a high worldwide incidence that is commonly seen as head and neck cancers, esophageal cancers, and non-small cell lung cancers. There is a poor prognosis for SCC due to potential recurrence and its metastatic tendency so the 5-year survival rate is very low. Target therapy is a novel and promising treatment strategy exhibiting great anti-tumor effects and survival benefits in SCC. This review summarizes current treatment strategies from clinical and experimental studies, including the agents targeting epidermal growth factor receptors, RNA polymerase, toll-like receptors, p38α MAPK, CXCR, and the related combination therapy regimens. However, there are still many challenges we have to face. It is a burning need to improve the development and availability of drug formulations.

Keywords: Drug, epidermal growth factor receptor, esophageal, head and neck, lung, squamous cell carcinoma, target therapy, toll-like receptor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 13 July, 2015
Page: [816 - 827]
Pages: 12
DOI: 10.2174/1871520615666150113103938
Price: $65

Article Metrics

PDF: 48